Prelude Therapeutics stock gains 2.72 percent as targets stay high

Published on 10/07/2026 at 02:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Six analysts assign Prelude Therapeutics stock a Moderate Buy consensus and an average USD 8.75 target. Q2 2026 revenue reached USD 5.704 million.

PRLD, US74065P1012, Illustration mit AI erstellt.

Prelude Therapeutics stock (ISIN US74065P1012) gained 2.72 percent to USD 3.7700 at the Nasdaq close on October 5, 2026. The move comes as analysts weigh the company's clinical pipeline against a still loss-making operating profile.

Analysts see room above USD 8.75

According to MarketBeat on October 1, 2026, six analysts carried a Moderate Buy consensus. Four analysts rated the stock Buy, one Hold and one Sell, while the average 12-month price target stood at USD 8.75.

Against the October 5 price of USD 3.7700, that consensus target places the price 56.91 percent below the target. The published target set included JPMorgan's USD 12.00 and H.C. Wainwright's USD 8.00, showing a wide spread in how analysts value the development-stage pipeline.

FDA clearance advances PRT13722

Prelude Therapeutics announced on September 10, 2026 that the FDA cleared its Investigational New Drug application for PRT13722, an oral KAT6A selective degrader for HR-positive and HER2-negative breast cancer.

The company said the first-in-human Phase 1 study is planned to begin enrolling patients in the fourth quarter of 2026. The trial will evaluate PRT13722 both as a monotherapy and in combination with endocrine and targeted therapies, with safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity among the study measures.

Q2 loss remains the counterweight

For the second quarter of 2026, Prelude reported USD 5.704 million in revenue and diluted EPS of negative USD 0.14, according to MarketBeat. The EPS loss was narrower than the negative USD 0.20 consensus estimate by USD 0.06, while quarterly revenue matched the USD 5.7 million estimate.

The financial profile keeps clinical execution central to the valuation. Prelude held USD 26.329 million in cash at June 30, 2026 and used USD 15.574 million in operating cash flow during the quarter, according to its reported financial data.

Stock remains below yearly high

Prelude Therapeutics shares closed at USD 3.7700 on Nasdaq on October 5, 2026, with a 52-week range of USD 1.1500 to USD 6.8300 and volume of 324,263 shares. The market capitalization was USD 300.9 million on that date, while the stock's year-to-date performance was 30.00 percent.